Stoke Therapeutics, Inc.
STOK
$19.56
-$0.12-0.61%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | 186.01% | 3,661.12% | 707.07% | 47.94% | 294.72% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 186.01% | 3,661.12% | 707.07% | 47.94% | 294.72% |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | 186.01% | 3,661.12% | 707.07% | 47.94% | 294.72% |
SG&A Expenses | 17.07% | 43.38% | 21.06% | 23.57% | 27.44% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 20.32% | 45.23% | 11.98% | 14.26% | 11.02% |
Operating Income | 6.96% | 492.08% | 53.85% | -10.17% | 11.79% |
Income Before Tax | 8.61% | 532.84% | 61.12% | -7.69% | 16.18% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 8.61% | 527.99% | 61.12% | -7.69% | 16.18% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 8.61% | 527.99% | 61.12% | -7.69% | 16.18% |
EBIT | 6.96% | 492.08% | 53.85% | -10.17% | 11.79% |
EBITDA | 6.74% | 501.73% | 54.68% | -10.78% | 11.81% |
EPS Basic | 12.67% | 442.07% | 69.35% | 15.39% | 33.57% |
Normalized Basic EPS | 12.67% | 445.99% | 69.34% | 15.38% | 33.58% |
EPS Diluted | 12.67% | 433.16% | 69.35% | 15.39% | 33.57% |
Normalized Diluted EPS | 12.67% | 437.04% | 69.34% | 15.38% | 33.58% |
Average Basic Shares Outstanding | 4.64% | 25.12% | 26.85% | 27.28% | 26.20% |
Average Diluted Shares Outstanding | 4.64% | 28.44% | 26.85% | 27.28% | 26.20% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |